Kornimate/medical-research-clean huggingface dataset:
predicting resting energy expenditure in critically ill patients by measuring lean body mass by us

Conditions: Resting Energy Expenditure

Summary: the study aims to correlate lean body mass (lbm) evaluated by musculoskeletal ultrasound with resting energy expenditure (ree) measured by indirect calorimetry and to generate a predictive equation of ree based on lbm, in addition to identifying other factors that may affect ree such as age, gender, and severity scores.

caloric needs in critically-ill patients fluctuate significantly over the course of the disease which might expose patients to either malnutrition or overfeeding.malnutrition is associated with deterioration of lean body mass (lbm), poor wound healing, increased risk of nosocomial infection, and weakened respiratory muscles. on the other hand overfeeding in medically compromised patients can promote lipogenesis, hyperglycemia, and exacerbation of respiratory failure. many factors may affect the resting energy expenditure (ree) through manipulation of oxygen consumption (vo2). one of the strongest determinants of ree is the lbm. a measurement of muscle mass and changes in muscle mass could thus provide an index of lbm in critically ill patients. at present, computerized tomography, magnetic resonance imaging and dual-energy x-ray absorptiometry (dxa) are widely used as reference methods for evaluating lbm in vivo. however, these methods are impractical in critically ill patients. more practically, ultrasound scanning is a simple, portable, safe, and a low-patient burden technique. several studies found that the use of ultrasound can be a good estimate to lbm. indirect calorimetry remains the accepted standard for determining the ree in the critically ill. indirect calorimetry measures oxygen consumption(vo2) and carbon dioxide excretion (vco2 ) (both in ml/min), which are used to calculate the respiratory quotient and the resting energy expenditure. although, the measured lbm has been shown as an important determinant of ree, there was no previous study tested the relationship between estimated lbm by ultrasound-based muscle thickness measurement and ree.

Eligibility criteria:
inclusion criteria: - patient requiring ventilatory support \> 24 hours exclusion criteria: * patient who will require fio2 more than 0.6. * air leak from the chest tube. * patient with body temperature \> 39oc. * patients with known endocrine dysfunction. * patients on parenteral nutrition

Keywords: lean body mass resting energy expenditure oxygen consumption indirect calorimetry carbon dioxide excretion respiratory quotient
outcome of patients admitted to pediatric intensive care for acute respiratory failure

Conditions: Pediatric Respiratory Diseases

Summary: this study aims to assess the quality of life of patients six months after admission to a pediatric intensive care unit for acute respiratory failure. children's quality of life will be assessed using the pedsql scale at 6 months. this is a prospective cohort diagnostic and prognostic study.


Eligibility criteria:
inclusion criteria: * admitted in the picu of grenoble-alps university hospital * for acute respiratory failure (code j960) requiring mechanical ventilation for at least 48hrs exclusion criteria: * already followed-up by a pediatric pulmonologist * with congenital disease * with long term ventilation * still admitted at 3 months
goal directed hemodynamic management and renal outcome after renal transplant surgery

Conditions: Renal Transplant Surgery

Summary: this study is designed to compare the incidence of delayed graft function in patients following renal transplant surgery with different perioperative hemodynamic managements: a goal directed hemodynamic management group (using picco) and a control group.

volume assessment and management during renal transplantation is one of the most challenging problems the anesthetist has to deal with. it seems sensible that individualized volume management and hydration therapy during the operation and during the stay at the intensive care unit could improve perfusion of the transplanted organ resulting in a better transplant function. aim of this study is to investigate the impact of a goal directed hemodynamic management on incidence of delayed graft function (dgf) after renal transplant surgery. therefore patients will be randomized in one of two groups, the picco group with goal directed hemodynamic management during operation and during the icu-stay and the control group with hemodynamic management performed according to heart rate, blood pressure and central venous pressure.

Eligibility criteria:
inclusion criteria: * renal transplant surgery * age ≥ 65 years * written informed consent exclusion criteria: * contraindications for an arterial line in the femoral artery: * stents * bypasses * severe peripheral artery occlusive disease

Keywords: renal transplant surgery hemodynamic management picco delayed graft function
blood flow restriction in improving muscle strength of patients with hemophilic knee arthropathy

Conditions: Hemophilia

Summary: background. the main physical sequela of patients with hemophilia is the development of a progressive, degenerative intra-articular lesion, known as hemophilic arthropathy). this sequela is manifested by chronic pain, limited range of motion, axial abnormalities, and periarticular muscle atrophy. objective. to assess the safety and effectiveness of an intervention through blood flow restriction, regarding the frequency of bleeding and the improvement in muscle activation and strength, range of motion, functionality, joint pain, joint status and the perception of quality of life in patients with hemophilic arthropathy. knee and ankle. study design. randomized, multicenter, single-blind clinical study. method. 60 patients with hemophilia a and b will be recruited in this study. patients will be recruited in 6 regions of spain. the dependent variables will be: bleeding frequency (self-registration), pain (measured with the visual analog scale and pressure algometer), quality of life (sf-36 scale), joint status (hemophilia joint health score scale), strength (dynamometer) and muscle activation (surface electromyograph), range of motion (goniometer) and functionality (timed up and go test). three evaluations will be carried out: pre-treatment, post-treatment and after a follow-up period of 4 weeks. expected results. observe the safety of blood flow restriction in hemophilia patients. to analyze the efficacy of blood flow restriction in improving muscle strength and activation, range of motion, chronic pain, functionality, and the perception of quality of life in patients with hemophilic knee and ankle arthropathy.


Eligibility criteria:
inclusion criteria: * patients diagnosed with hemophilia a and b * people with a medical diagnosis of hemophilic knee arthropathy * adults (\> 18 years) * in prophylactic treatment regimen or on demand with fviii/fix concentrates. * failure to sign the informed consent document exclusion criteria: * patients with neurological or cognitive alterations that prevent understanding of the questionnaires * amputee patients, epileptics or patients with severe vision problems * patients who are receiving physiotherapy treatment at the time of the study

Keywords: hemophilic arthropathy blood flow restriction physiotherapy muscular strength muscle activation range of motion chronic pain functionality quality of life
respiratory oscillometry for the prediction of bronchopulmonary dysplasia

Conditions: Bronchopulmonary Dysplasia

Summary: the goal of this observational study is to learn about the correlation between respiratory system reactance, as assessed by respiratory oscillometry, and respiratory outcomes in preterm infants born before 32 weeks of gestation. the main question it aims to answer is if the reactance z-score at 7 postnatal days adds to relevant clinical factors in the prediction of bronchopulmonary dysplasia. participants will receive respiratory oscillometry measurements at 7 ± 2 postnatal days.


Eligibility criteria:
inclusion criteria: * born before 32 weeks post-menstrual age exclusion criteria: * congenital abnormalities * inherited disorders of metabolism

Keywords: respiratory oscillometry respiratory system reactance lung mechanics infant lung function testing
postmarketing surveillance study of atrovent® inhalets in chronic obstructive airways disease

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: to obtain further information on the tolerability of atrovent® inhalets in the treatment of chronic obstructive airways disease under conditions of daily practice


Eligibility criteria:
inclusion criteria: * primarily, patients with chronic obstructive airways disease * only patients who had not been treated with atrovent® in the last year were to be considered for inclusion exclusion criteria: - contraindications listed in the instructions for use/summary of product characteristics for atrovent® inhalets
zilver ptx post-market study in japan

Conditions: Peripheral Arterial Disease (PAD)

Summary: japanese post market clinical study of the zilver ptx device.


Eligibility criteria:
inclusion criteria: * symptomatic peripheral arterial disease (pad) involving the above-the-knee femoropopliteal arteries
glaukos® istent® trabecular micro-bypass stent system in conjunction with cataract surgery postmarket registry

Conditions: Primary Open-angle Glaucoma

Summary: the purpose of this study is to observe the safety of the glaukos® istent® trabecular micro-bypass stent model gts100 in conjunction with cataract surgery in subjects with mild to moderate open-angle glaucoma.


Eligibility criteria:
inclusion criteria: * consecutive subjects in whom implantation of the istent is attempted exclusion criteria: * please refer to approved indications in directions for use

Keywords: primary open-angle glaucoma (poag) trabecular meshwork istent
impact of maternal supplementation with dual megadose of vitamin a

Conditions: Hypovitaminosis; Vitamin A Deficiency

Summary: the purpose of this study is to evaluate the effect of maternal supplementation with 400,000 iu of oral retinol palmitate in the post-partum, the nutritional situation of the binomial mother-child, on growth and morbidity of children in breastfeeding in the first six months of life.

the effect will be assessed by the milk and blood.

Eligibility criteria:
inclusion criteria: * pregnant low-risk obstetric exclusion criteria: * premature birth * newborn babies with birth defects and / or other serious diseases

Keywords: hypovitaminosis a
hypoxic burden and sleepiness in treated osa patients

Conditions: Obstructive Sleep; OSA

Summary: the maintenance of wakefulness test (mwt) is widely used to objectively assess sleepiness and make safety-related decisions and epworth sleepiness scale (ess) is the most used scale used to assess subjective sleepiness in sleep medicine. besides obstructive sleep apnea measures are rapidly evolving and conventional measures such as apnea-hypopnea index (ahi) and oxygen desaturation index (odi) are increasingly being supplemented by measures of hypoxia such as hypoxic burden. residual ahi in treated osa have limited predictive value for objective sleepiness. therefore it seems particularly relevant to identify other predictors of both subjective and objective sleepiness. this study aims at studying the influence of hypoxic burden as measure of both subjective or objective sleepiness. we hypothesize that impaired nocturnal oxygenation might influence brain functioning during wakefulness and result in sleepiness as assessed by ess and mwt.


Eligibility criteria:
inclusion criteria: * osa hospitalised to undergo both polysomnography (psg) and the 40-min mwt in the center for sleep medicine and respiratory disease, lyon academic hospital from september 2017 to march 2020. exclusion criteria: * - age \&lt;18 years * refusal to participate in the study * diagnosis of central disorder of hypersomnolence * missing data on the mwt * epworth sleepiness scale (ess) * apnea-hypopnea index (ahi).

Keywords: polysomnography polygraphy hypoxic burden
a method of calculating the shortest incision for internal fixation of zygomatic arch fracture

Conditions: Zygomatic Fractures

Summary: in this study, a new method was proposed to calculate the length of sideburns mini incision for zygomatic arch fracture. the purpose of this study was to compare the sideburns mini incision calculated by this method with the coronal scalp incision, so as to determine the therapeutic effect and advantages of sideburns mini incision calculated by this method.

eighty patients with zygomatic arch fracture were treated with surgical intervention. forty patients were treated with sideburns mini incision, and the other forty patients were treated with coronal scalp incision. data such as incision length, operation time and postoperative complications were recorded. the follow-up periods were 6 months.

Eligibility criteria:
inclusion criteria: 1. clinical and imaging diagnosis of zygomatic arch fracture or zygomatic maxillary complex fracture. 2. fracture fragments are obviously displaced, which affects the appearance and function of the patient. simple prying is instable and requires open reduction and internal fixation. 3. no previous surgical treatment. exclusion criteria: 1. accompanied by multiple fractures of mandible, nasal bone and so on. 2. there are traumatic scars in the operation area, which can be accessed through the original wound. 3. history of bone disease and / or wound healing disorders. 4. mental and intellectual disorders.

Keywords: zygomatic arch fracture fixation
vaccine effectiveness of rv1 in a naïve population

Conditions: Rotavirus Infections; Gastroenteritis; Diarrhea

Summary: rotavirus (rv) is the leading cause of severe gastroenteritis (ge) in young children. the cumulative risk of ge hospitalizations and hospital stays of \< 24 hours is 1/25, which would amount to 13,600 canadian children \< 5 years. the incidence of nosocomial rv infections is an average of 8/10,000 patient-days in children \< 5 years. an immunization program with a live-attenuated monovalent oral rv vaccine (rv1 - rotarix® from gsk) will be implemented, free of charge, in the province of quebec in november 2011. to provide an accurate portrait of the disease and give critical information to the public health agencies as they struggle to control costs, we aim to evaluate the accuracy of surveillance for rv and other diseases with similar characteristics; estimate selection bias in passive laboratory-based surveillance; and estimate the agreement between surveillance time-series created from passive and active surveillance data sources.

in november 2011, quebec implemented a publicly-funded rv1 vaccination program with its routine administration at 2 and 4 months of age. from february 1, 2012 - may 31, 2014, we conducted prospective, active surveillance for acute rotavirus gastroenteritis at the montreal children's hospital and centre hospitalier universitaire sainte-justine, located in montreal, and centre hospitalier universitaire de sherbrooke, located in sherbrooke. active surveillance was approved by research ethics boards at each hospital.

Eligibility criteria:
inclusion criteria: * child less than 3 years old cases: * acute gastroenteritis (within 7 days of hospital visit) * able to provide a stool specimen for rv elisa testing * rotavirus positive controls: * visited the ed or admitted for a non-rotavirus gastroenteritis * visited the ed or admitted for acute respiratory infections without gastroenteritis symptoms exclusion criteria: * immunocompromised children * prior history of intussusception * admission to nicu between 6 to 15 weeks of life, for \>6 weeks * child less than 56 days of life (8 weeks) * child vaccinated with rotateq (merck)

Keywords: rotavirus gastroenteritis vaccination pediatrics
a message framing intervention for increasing parental acceptance of human papillomavirus vaccination

Conditions: Cervical Cancer; Anal Cancer; Penile Cancer

Summary: the goal of this study is to determine the effects of message framing (gain vs. loss) on african american parents' acceptance of the hpv vaccine and how such effects are moderated by parents' salient beliefs prior to message exposure. participants are randomized into gain and loss conditions in which they view either gain-framed or loss-framed hpv vaccination messages. key outcome variables include parents' attitudes and intentions toward vaccinating their children against hpv.

the goal of this study is to determine the effects of message framing (gain vs. loss) on african american parents' acceptance of the hpv vaccine and how such effects are moderated by parents' salient beliefs prior to message exposure. participants recruited from local communities and online panels will complete a computer-assisted survey. in the survey participants will first answer questions related to their beliefs about hpv and the hpv vaccine (e.g., perceived susceptibility, perceived severity, perceived efficacy, perceived safety, etc.), as well as other background information. then they will be presented with either a gain-framed or loss-framed human papillomavirus vaccination message. after the message exposure, they will answer questions related to their attitudes toward hpv vaccination, intentions to vaccinate their children, as well as other message response measures. eligible participants are at least 21 years old, self-identify as african american, and are custodial parents or caretakers of at least one child ages 9-17 who has not initiated the hpv vaccine series.

Eligibility criteria:
inclusion criteria: * 18 years or older * self-identify as african american * custodial parent or caretaker of at least one child under the age of 18 who has not been fully vaccinated against hpv. * has access to internet to complete the study exclusion criteria: * younger than 18 years * does not self-identify as african american * not a custodial parent or caretaker of at least one child under the age of 18 who has not been fully vaccinated against hpv. * has no access to internet to complete the study
a clinical trial to evaluate prophylactic emicizumab versus no prophylaxis in hemophilia a participants without inhibitors

Conditions: Hemophilia A

Summary: this is a randomized, global, multicenter, open-label, phase 3 clinical study in participants with severe hemophilia a without inhibitors against factor viii (fviii) who are 12 years or older. the study evaluates two prophylactic emicizumab regimens versus no prophylaxis in this population with emphasis on efficacy, safety, and pharmacokinetics.


Eligibility criteria:
inclusion criteria: * body weight \>/= 40 kilogram (kg) at the time of screening * diagnosis of severe congenital hemophilia a * documentation of the details of prophylactic or episodic fviii treatment and of number of bleeding episodes for at least the last 24 weeks * adequate hematologic function * adequate hepatic function * adequate renal function * for women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of less than (\<) 1 percent (%) per year during the treatment period and for at least 5 elimination half-lives (24 weeks) after the last dose of study drug exclusion criteria: * inherited or acquired bleeding disorder other than hemophilia a * previous or current treatment for thromboembolic disease or signs of thromboembolic disease * conditions that may increase risk of bleeding or thrombosis * history of clinically significant hypersensitivity associated with monoclonal antibody therapies or components of the emicizumab injection * known human immunodeficiency virus (hiv) infection with cluster of differentiation (cd) 4 count \ ) 200 and meet all other criteria are eligible * use of systemic immunomodulators at enrollment or planned use during the study, with the exception of anti-retroviral therapy * participants who are at high risk for thrombotic microangiopathy (tma) (for example, have a previous medical or family history of tma), in the investigator's judgment * concurrent disease, treatment, or abnormality in clinical laboratory tests that could interfere with the conduct of the study, may pose additional risk, or would, in the opinion of the investigator, preclude the participant's safe participation in and completion of the study * planned surgery (excluding minor procedures) during the study * receipt of emicizumab in a prior investigational study; an investigational drug to treat or reduce the risk of hemophilic bleeds within 5 half-lives of last drug administration; a non-hemophilia-related investigational drug concurrently, within last 30 days or 5 half-lives, whichever is shorter * pregnant or lactating, or intending to become pregnant during the study

Keywords: hemophilia a emicizumab
montelukast for prevention & treatment of ohss

Conditions: Ovarian Hyperstimulation Syndrome

Summary: montelukast \& dydrgesteron will be given to cases with suspected or proven ovarian hyperstimulation in one group in comparison with dydrogesteron alone in the other group.

patients with high risk for ovarian hyperstimulation will undergo a freeze-all protocol then montelukast \& dydrgesteron will be given to cases with suspected or proven ovarian hyperstimulation in one group in comparison with dydrogesteron alone in the other group.

Eligibility criteria:
inclusion criteria: * pcos high responders high numbers of ovum retrieved exclusion criteria: * hypersensitivity to any drug components phenylketonuria patients depression liver dysfunction

Keywords: ovarian hyperstimulation syndrome montelukast
type ii diabetes influence on left ventricular remodeling and outcomes in patients undergoing aortic valve replacement surgery.

Conditions: Type II Diabetes

Summary: this project focuses on the physiopathology of left ventricular remodeling associated with type ii diabetes in patients with aortic valve stenosis referred for surgical aortic valve replacement. the main objective is to compare the reverse left ventricular remodeling between patients with type ii diabetes and case-control patients without diabetes at one(1) year after surgical aortic valve replacement. the secondary objectives are : 1. assess the influence of type ii diabetes on left ventricular remodeling in patients presenting with aortic valve stenosis, 2. assess the predictive value of myocardial fibrosis and other lv characteristics present prior to aortic valve surgery on the lv reverse remodeling and their influence on cardiovascular events at one (1) year after surgery, 3. assess the influence of type ii diabetes on cardiovascular morbidity and mortality post aortic valve surgery. the investigators main hypothesis is that patients with type ii diabetes and aortic valve stenosis requiring aortic valve replacement have poorer lv function and less favorable post surgery clinical outcomes than patients without type ii diabetes.


Eligibility criteria:
inclusion criteria: * age \> 18 years * arm 1: treated type ii diabetes, arm 2: absence of type ii diabetes * aortic valve stenosis * lvef \> 50% with no kinetic abnormalities * non significant obstructive coronary artery disease * absence of gadolinium enhanced mri contraindications * informed consent signed * patient affiliated to the french social security. exclusion criteria: * chronic arrhythmia or absence of sinus rhythm * past history of cardiomyopathy or coronary insufficiency * significant coronaropathy seen during the coronary angiography with \>50% degree stenosis prior to aortic valve replacement * hemodynamically significant valvular dysfunction other than aortic stenosis (grade 2 mitral or aortic insufficiency, mitral valve stenosis \< 1.5 cm2) * systemic chronic inflammatory disease leading to cardiac injury (scleroderma) * renal insufficiency (clearance \< 30 ml/min) * insufficient transthoracic echocardiography echogenicity * type i diabetes mellitus * uncontrolled hypertension (\> 180/100 mm hg)

Keywords: type ii diabetes aortic valve stenosis left ventricular remodeling aortic valve replacement surgery